Fluvastatin Plus Dipyridamole Suppresses Canine Hemangiosarcoma Growth in Patient‐Derived Xenograft Models Through Lactate Dehydrogenase‐Associated Cholesterol/Lipid Metabolism
- 1Laboratory of Comparative Pathology, Department of Clinical Sciences, Faculty of Veterinary Medicine Hokkaido University Sapporo Hokkaido Japan
- 2Translational Research Unit, Veterinary Teaching Hospital, Faculty of Veterinary Medicine Hokkaido University Sapporo Hokkaido Japan
- 3Cancer Research Unit, One Health Research Center Hokkaido University Sapporo Hokkaido Japan
Abstract
Tumour cells commonly exhibit aerobic glycolysis and produce lactate despite oxygen availability. Lactate dehydrogenase (LDH) catalyses pyruvate‐lactate interconversion and regulates intracellular lactate levels. Endothelial cells also depend on glycolysis for ATP production, which prompted us to investigate LDH in canine hemangiosarcoma (HSA), a malignant endothelial tumour. We inhibited LDH with (R)‐GNE‐140 or sodium oxamate in two canine HSA cell lines (HU‐HSA‐2 and HU‐HSA‐3) and generated HU‐HSA‐3 clones with knockout of LDHA or LDHB to evaluate the effects of LDH perturbation. (R)‐GNE‐140 and sodium oxamate suppressed proliferation and reduced global histone lactylation levels in both cell lines. mRNA‐sequencing (mRNA‐seq) of (R)‐GNE‐140‐treated HU‐HSA‐2 cells identified cholesterol/lipid metabolism‐related gene sets among the top negatively enriched pathways. Representative cholesterol/lipid metabolism genes such as SREBF2, SQLE and LDLR responded differently depending on cell lines and inhibitors. (R)‐GNE‐140 decreased these genes in HU‐HSA‐2 but not HU‐HSA‐3, whereas sodium oxamate decreased them in HU‐HSA‐3 with limited effects in HU‐HSA‐2. In HU‐HSA‐3, LDHA and LDHB knockout clones decreased SREBP2 expression and reduced the number of lipid droplets. Fluvastatin, a cholesterol metabolism inhibitor, inhibited HSA cell growth in vitro but did not significantly suppress tumour growth in two HSA patient‐derived xenograft (PDX) models. In contrast, combined fluvastatin and dipyridamole treatment inhibited proliferation in vitro and tumour growth in PDX models. Collectively, these results suggest a context‐dependent association between LDH and cholesterol/lipid metabolism in canine HSA cell lines and provide a rationale for further evaluation of combined cholesterol pathway inhibition.
Related
- Synergistic fluvastatin-nanotherapy suppresses DEPDC1-associated glycolysis and exosomal CCL2 to modulate the immune microenvironment in lung adenocarcinoma.
- Dietary tryptophan restriction selectively suppresses lipogenesis, lowers cholesterol, and reduces adiposity without altering food consumption
- Medicarpin suppresses gastric cancer growth in association with inhibition of mevalonate pathway-associated cholesterol biosynthesis
- Fluvastatin Prevents Renal Dysfunction and Vascular NO Deficit in Apolipoprotein E-Deficient Mice
- Canine Hemangiosarcoma Cell Lines In Vitro Platform Captures Morphological, Functional, and Molecular Diversity.
BibTeX
@article{suzuki2026fluvastatin,
title = {{Fluvastatin Plus Dipyridamole Suppresses Canine Hemangiosarcoma Growth in Patient‐Derived Xenograft Models Through Lactate Dehydrogenase‐Associated Cholesterol/Lipid Metabolism}},
author = {Tamami Suzuki and Suzune Tanaka and Keika Kishimoto and Takuma Goto and Jumpei Yamazaki and Takashi Kimura and Keisuke Aoshima},
journal = {Veterinary and Comparative Oncology},
year = {2026},
month = aug,
doi = {10.1111/vco.70097},
url = {https://doi.org/10.1111/vco.70097},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Fluvastatin Plus Dipyridamole Suppresses Canine Hemangiosarcoma Growth in Patient‐Derived Xenograft Models Through Lactate Dehydrogenase‐Associated Cholesterol/Lipid Metabolism
AU - Tamami Suzuki
AU - Suzune Tanaka
AU - Keika Kishimoto
AU - Takuma Goto
AU - Jumpei Yamazaki
AU - Takashi Kimura
AU - Keisuke Aoshima
PY - 2026
DA - 2026/08/10
JO - Veterinary and Comparative Oncology
DO - 10.1111/vco.70097
UR - https://doi.org/10.1111/vco.70097
AB - Tumour cells commonly exhibit aerobic glycolysis and produce lactate despite oxygen availability. Lactate dehydrogenase (LDH) catalyses pyruvate‐lactate interconversion and regulates intracellular lactate levels. Endothelial cells also depend on glycolysis for ATP production, which prompted us to investigate LDH in canine hemangiosarcoma (HSA), a malignant endothelial tumour. We inhibited LDH with (R)‐GNE‐140 or sodium oxamate in two canine HSA cell lines (HU‐HSA‐2 and HU‐HSA‐3) and generated HU‐HSA‐3 clones with knockout of LDHA or LDHB to evaluate the effects of LDH perturbation. (R)‐GNE‐140 and sodium oxamate suppressed proliferation and reduced global histone lactylation levels in both cell lines. mRNA‐sequencing (mRNA‐seq) of (R)‐GNE‐140‐treated HU‐HSA‐2 cells identified cholesterol/lipid metabolism‐related gene sets among the top negatively enriched pathways. Representative cholesterol/lipid metabolism genes such as SREBF2, SQLE and LDLR responded differently depending on cell lines and inhibitors. (R)‐GNE‐140 decreased these genes in HU‐HSA‐2 but not HU‐HSA‐3, whereas sodium oxamate decreased them in HU‐HSA‐3 with limited effects in HU‐HSA‐2. In HU‐HSA‐3, LDHA and LDHB knockout clones decreased SREBP2 expression and reduced the number of lipid droplets. Fluvastatin, a cholesterol metabolism inhibitor, inhibited HSA cell growth in vitro but did not significantly suppress tumour growth in two HSA patient‐derived xenograft (PDX) models. In contrast, combined fluvastatin and dipyridamole treatment inhibited proliferation in vitro and tumour growth in PDX models. Collectively, these results suggest a context‐dependent association between LDH and cholesterol/lipid metabolism in canine HSA cell lines and provide a rationale for further evaluation of combined cholesterol pathway inhibition.
SN - 1476-5810
SN - 1476-5829
ER -